Smoking cessation 3: Nicotinic partial agonists in smoking cessation - Varenicline and cytisine
Cigarette smoking is the most preventable cause of illness, death, and excess healthcare costs in the UK. Most smokers want to stop smoking and intend to stop at some point. In this third article in our series on smoking cessation in primary care, we look at the evidence for the use of nicotinic par...
Κύριοι συγγραφείς: | Aveyard, P, Parsons, A, Begh, R |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
2009
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
An integrated approach to pharmacotherapy in smoking cessation: the role of varenicline, bupropion, cytisine, and nicotine replacement therapy
ανά: Kacper Więcław, κ.ά.
Έκδοση: (2023-08-01) -
The place of varenicline in smoking cessation treatment.
ανά: Aveyard, P
Έκδοση: (2008) -
Smoking cessation 4: Antidepressants for smoking cessation - Bupropion and nortriptyline
ανά: Aveyard, P, κ.ά.
Έκδοση: (2010) -
Placebo-controlled trial of cytisine for smoking cessation.
ανά: West, R, κ.ά.
Έκδοση: (2011) -
Nicotine receptor partial agonists for smoking cessation
ανά: Livingstone-Banks, J, κ.ά.
Έκδοση: (2023)